Oramed Pharmaceuticals (ORMP) Gains from Sales and Divestitures (2021 - 2025)

Oramed Pharmaceuticals has reported Gains from Sales and Divestitures for 5 years, with the latest figure at $1.9 million in Q4 2025.

• For the quarter ending Q4 2025, Gains from Sales and Divestitures rose 103.05% year-over-year to $1.9 million; the trailing twelve-month figure through Dec 2025 stood at $1.9 million (up 103.05% YoY), and the FY2025 full-year result was $1.9 million, up 103.05% from the prior year.
• Gains from Sales and Divestitures for Q4 2025 stood at $1.9 million, up from $925937.0 in the prior quarter.
• The five-year high for Gains from Sales and Divestitures was $1.9 million in Q4 2025, with the low at $4000.0 in Q4 2022.
• Historically, Gains from Sales and Divestitures has averaged $713666.2 across 5 years, with a median of $521625.0 in 2023.
• Annual changes were most pronounced in 2023 — Gains from Sales and Divestitures jumped 12940.62% — and 2024, when it surged 77.51%.
• Oramed Pharmaceuticals' Gains from Sales and Divestitures stood at $236665.0 in 2021, then sank by 98.31% to $4000.0 in 2022, then jumped by 12940.62% to $521625.0 in 2023, then surged by 77.51% to $925937.0 in 2024, then surged by 103.05% to $1.9 million in 2025.
• The last three Gains from Sales and Divestitures figures came in at $1.9 million (Q4 2025), $925937.0 (Q4 2024), and $521625.0 (Q4 2023), per Business Quant data.